Mizuho Securities analyst Difei Yang maintained a Buy rating on Selecta Biosciences (NASDAQ: SELB) today and set a price target of $30. The company’s shares closed on Friday at $12.75.
Yang commented:
“We spoke with management and we expect a smooth transition to occur as they step down. Both CEO and CMO will remain in their respective roles through the beginning of the phase 3 trial of SEL-212.”
According to TipRanks.com, Yang is a 5-star analyst with an average return of 22.0% and a 55.6% success rate. Yang covers the Healthcare sector, focusing on stocks such as Nightstar Therapeutics Limited, Alder Biopharmaceuticals, and Audentes Therapeutics.
Currently, the analyst consensus on Selecta Biosciences is Moderate Buy and the average price target is $35, representing a 174.5% upside.
In a report issued on June 15, Canaccord Genuity also maintained a Buy rating on the stock with a $40 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $24.02 and a one-year low of $7.95. Currently, Selecta Biosciences has an average volume of 244.3K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The firm produces the Synthetic Vaccine Particles (SVP) platform for immune tolerance and immune stimulation.
